SNOA - Sonoma Pharmaceuticals, Inc.
| Previous Close | 3.83 |
| Open | 3.85 |
| Bid | 3.63 x 600 |
| Ask | 3.96 x 400 |
| Day's Range | 3.81 - 3.95 |
| 52 Week Range | 3.50 - 7.75 |
| Volume | 74,305 |
| Avg. Volume | 137,539 |
| Market Cap | 18.404M |
| Beta | 0.49 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.79 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.50 |
- GlobeNewswire•4 days ago
Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products
PETALUMA, Calif., April 17, 2018-- Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions ...
- ACCESSWIRE•12 days ago
Blog Exposure - FDA Granted New 510(k) Clearance to Sonoma Pharma’s Antimicrobial Post-Therapy Gel
LONDON, UK / ACCESSWIRE / April 09, 2018 / Active-Investors.com has just released a free research report on Sonoma Pharma, Inc. (NASDAQ: SNOA ). If you want access to this report all you need to do is ...
- Benzinga•16 days ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Intercept Pharmaceuticals Inc (NASDAQ: ICPT ), a biopharmaceutical ...
- MarketWatch•16 days ago
Sonoma Pharmaceuticals shares jump 30% premarket after FDA approves skin gel
Sonoma Pharmaceuticals Inc. shares surged 30% in premarket trade Thursday, after the company said the U.S. Food and Drug Administration has approved its antimicrobial post-therapy gel. The gel is aimed ...
- GlobeNewswire•16 days ago
Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel
PETALUMA, Calif., April 05, 2018-- Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets unique and effective solutions for management of dermatological conditions ...
- GlobeNewswire•25 days ago
Sonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution
PETALUMA, Calif., March 27, 2018-- Sonoma Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions ...
- GlobeNewswire•last month
Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018
PETALUMA, Calif., March 09, 2018-- Sonoma Pharmaceuticals, Inc. today announced that Jim Schutz, Sonoma CEO, will be a featured presenter at the Roth Capital Partners 30th Annual Growth Stock Conference ...
- ACCESSWIRE•last month
Dawson James Securities Announces Closing of $5 Million Public Offering for Sonoma Pharmaceuticals, Inc.
BOCA RATON, FL / ACCESSWIRE / March 7, 2018 / Dawson James Securities, Inc. in conjunction with Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, Warrants - SNOAW) today announced the March 6th closing of a ...
- GlobeNewswire•last month
Sonoma Pharmaceuticals Announces Closing of $5 Million Public Offering of Common Stock
PETALUMA, Calif., March 06, 2018-- Sonoma Pharmaceuticals, Inc. today announced the closing of a public offering of 1,428,570 shares of common stock at a public offering price of $3.50 per share.. The ...
- GlobeNewswire•2 months ago
Sonoma Pharmaceuticals Announces Pricing of $5 Million Public Offering of Common Stock
PETALUMA, Calif., March 02, 2018-- Sonoma Pharmaceuticals, Inc. today announced the pricing of a“ best efforts” public offering of up to 1,428,571 shares of common stock at a public offering price of $3.50 ...
- ACCESSWIRE•2 months ago
Blog Exposure - Novo Nordisk’s Ozempic is Approved in the EU for the Treatment of Type 2 Diabetes
Stock Monitor: Sonoma Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 12, 2018 / Active-Investors.com has just released a free research report on Novo Nordisk A/S (NYSE: NVO ). If you ...
- GlobeNewswire•2 months ago
Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46%
Product revenue up 12% compared to September 2017 quarter U.S. product revenue up 27% compared to the September 2017 quarter Cash on hand equals $8.6 million at quarter end Conference Call Begins at 4:30pm ...
- ACCESSWIRE•2 months ago
Sonoma Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 7, 2018 / Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA ) will be discussing their earnings results in their Q3 Earnings Call to be held on February 7, 2018 at 4:30 PM ...
- GlobeNewswire•3 months ago
Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2018 Financial Results and Conference Call
PETALUMA, Calif., Jan. 25, 2018-- Sonoma Pharmaceuticals, Inc. today announced that financial results for its fiscal third quarter 2018, ended December 31, 2017, will be released after the U.S. markets ...
Capital Cube•4 months agoSonoma Pharmaceuticals, Inc. :SNOA-US: Earnings Analysis: Q2, 2018 By the Numbers : January 1, 2018
Categories: Yahoo FinanceGet free summary analysis Sonoma Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 4.33 million, Net Earnings of USD -2.87 million. Gross margins narrowed from 50.68% to 42.73% compared to the same period last year, operating (EBITDA) margins now -63.01% from -45.84%. Change in operating ... Read more (Read more...)
- Simply Wall St.•5 months ago
Does Sonoma Pharmaceuticals Inc’s (SNOA) Recent Track Record Look Strong?
In this commentary, I will examine Sonoma Pharmaceuticals Inc’s (NASDAQ:SNOA) latest earnings update (30 September 2017) and compare these figures against its performance over the past couple of years, asRead More...
- Simply Wall St.•5 months ago
What You Must Know About Sonoma Pharmaceuticals Inc’s (SNOA) Financial Strength
Investors are always looking for growth in small-cap stocks like Sonoma Pharmaceuticals Inc (NASDAQ:SNOA), with a market cap of USD $19.24M. However, an important fact which most ignore is: howRead More...
- ACCESSWIRE•5 months ago
Sonoma Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA ) will be discussing their earnings results in their Q2 Earnings Call to be held on November 9, 2017 at 4:30 PM ...
- Capital Cube•6 months ago
ETFs with exposure to Sonoma Pharmaceuticals, Inc. : October 25, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Sonoma Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to SNOA-US. Comparing the performance and risk of Sonoma Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
